Germany-based Boehringer Ingelheim and Sanofi have closed a strategic and smooth exchange of their Consumer and Animal Health Business in India. This swap of over 80 brands will enable both pharma giants further strengthen their expertise in their respective fields. Today, established as a leader in fields catering to both human and animal health, Boehringer Ingelheim globally operates through 145 affiliates and has close to 50,000 employees.
Their focus involves R&D, manufacturing and marketing new therapies of value for animal and human health. Sharad Tyagi, Managing Director, Boehringer Ingelheim (India) said, “This swap is an important highlight and milestone for both Boehringer Ingelheim and Sanofi and will enable both organisations strengthen their foothold in this increasingly competitive field. Our unified goal is to continue to deliver current and prospective customers with sustained quality and value-added products. Boehringer Ingelheim seeks to continue to build a strong and innovative brand, both globally and in India.” Boehringer Ingelheim’s new Animal Health Business in India will be headed by Dr Sandeep Karkhanis, Merial. Dr Shailesh Ayyangar, Managing Director (India) and Vice President (South Asia), Sanofi said, “With the successful closure of the swap deal in India, both companies have achieved a major landmark.
This swap of the Consumer Healthcare Business of Boehringer Ingelheim (BI) and Sanofi’s Animal Health Business will facilitate both companies to pursue their respective strategic aspirations. At Sanofi, we are excited to embrace the incoming CHC brands and people associated with this business, as this is in line with our stated objective of boosting our presence in consumer healthcare in India. We also know that our Animal Health Business and people associated with it will now be part of a highly committed and focused BI, which is one of the world’s leading companies in the Animal Health Business.”